Home › Funds › Frazier Life Sciences Management, L.P. › ACAD
Frazier Life Sciences Management, L.P. position in ACAD
ACADIA PHARMACEUTICALS INC · Health Care
Frazier Life Sciences Management, L.P. reported holding 1,438,198 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$36.4M, representing 0.79% of its reported portfolio and ranking #25 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed ACAD holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s ACAD position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in ACAD in Q3 2023 at 630,897 shares (US$13.1M). The position peaked in Q2 2026 at 1,438,198 shares, worth US$36.4M. Across 11 filings, Frazier Life Sciences Management, L.P. increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 1,438,198 shares valued at US$36.4M. Notable position changes include a 36% trim in Q1 2024 (shares fell 12% over the following quarter), a 111% increase in Q4 2025 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 630.90K | $13.15M | New |
| Q4 2023 | 730.92K | $22.89M | Add |
| Q1 2024 | 470.34K | $8.70M | Reduce |
| Q2 2024 | 470.34K | $7.64M | Hold |
| Q3 2024 | 470.34K | $7.23M | Hold |
| Q4 2024 | 470.34K | $8.63M | Hold |
| Q1 2025 | 470.34K | $7.81M | Hold |
| Q3 2025 | 613.84K | $13.10M | New |
| Q4 2025 | 1.30M | $34.65M | Add |
| Q1 2026 | 1.44M | $32.01M | Add |
| Q2 2026 | 1.44M | $36.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACAD and 13F data
ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in ACAD — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.09B), RTW INVESTMENTS, LP (US$180.8M), Palo Alto Investors LP (US$72.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACAD
- BAKER BROS. ADVISORS LP 42.91M sh · $1.09B · Q2 2026
- RTW INVESTMENTS, LP 7.14M sh · $180.76M · Q2 2026
- Palo Alto Investors LP 2.86M sh · $72.46M · Q2 2026
- BRAIDWELL LP 1.65M sh · $41.65M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held ACAD?
Frazier Life Sciences Management, L.P. has disclosed ACAD holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
What is Frazier Life Sciences Management, L.P.'s current position in ACAD?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 1.44M shares of ACAD (ACADIA PHARMACEUTICALS INC), valued at $36.39M, representing 0.79% of its reported portfolio and ranking #25.
Has Frazier Life Sciences Management, L.P. been buying or selling ACAD?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in ACAD. The position peaked in Q2 2026 at 1.44M shares.
Which other funds hold ACAD?
Other major institutional holders of ACAD include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Palo Alto Investors LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.